Clinical Pharmacology of FYU-981 (Subjects With Renal Insufficiency)

• Status: Completed
• Trial end date: 2015-03-01
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to assess the pharmacokinetics, pharmacodynamics and safety after single oral administration of FYU-981 to subjects with renal insufficiency and with normal renal function.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Fuji Yakuhin Co., Ltd.
• Treatments: Dotinurad

Criteria

Inclusion Criteria:

• Japanese adult subjects

• Body mass index: >=18.5 and <30.0

Exclusion Criteria:

• Subjects with any disease or any history of diseases that might be unsuitable for participation in the clinical study